v3.26.1
COMMITMENTS AND CONTINGENCIES (Tables)
 3 Months Ended
Jul. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
Schedule of contractual obligation, fiscal year maturity
     
Payment Due Date
$ 50,000* Pre-IND Meeting - Completed September 2019
     
$ 65,000* IND application filing - Completed June 2021
     
$ 190,000* Upon first dosing of patient in a clinical trial - Completed December 2021
     
$ 500,000* Upon completion of first clinical trial - Completed March 2022
     
$ 1,250,000 Upon first patient treated in a Phase III clinical trial
     
$ 10,000,000 Upon FDA NDA approval
*Milestone met and completed

 

ALZN002 License:

 

Payment Due Date
$ 50,000* Upon IND application - Completed January 2022
     
$ 50,000 Upon first dosing of patient in first Phase I clinical trial
     
$ 500,000 Upon completion of first Phase IIB clinical trial
     
$ 1,000,000 Upon first patient treated in a Phase III clinical trial
     
$ 10,000,000 Upon first commercial sale
*Milestone met and completed

 

Additional AL001 Licenses:

 

Payment Due Date
$ 2,000,000 Upon first patient treated in a Phase III clinical trial
     
$ 16,000,000 First commercial sale